{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T15:23:10Z","timestamp":1782055390614,"version":"3.54.5"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing has emerged as a promising approach in cancer treatment, with various studies proposing the use of existing drugs for the treatment of bladder cancer. In this context, we previously established an in silico repurposing strategy using patient omics signatures, identifying drugs and compounds with the potential to reverse nonmuscle-invasive bladder cancer (NMIBC) to less aggressive subtypes. In the present study, we expanded our in silico approach to verify a list of compounds with potential antitumor activity against MIBC. We investigated the efficacy of the predicted candidates in a group of different bladder cancer cell lines, including NMIBC and MIBC. The most potent compound for decreasing cell viability was amiodarone, an antiarrhythmic drug widely used in the field of cardiology. Amiodarone reduced cell proliferation and colony formation capacity, with a stronger effect on the most aggressive invasive models, validating our repurposing pipeline. The drug additionally induced cell death and inhibited the activity of mTOR and its target protein S6, suggesting that the anticancer effect of the drug is, in part, mediated by inhibition of the mTOR signaling pathway. Furthermore, the administration of amiodarone in a xenograft MIBC mouse model reduced tumor growth without inducing toxicity. Altogether, we demonstrated that amiodarone is a potential repurposed drug for bladder cancer, which might be especially effective in MIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Treatment of advanced bladder cancer remains a therapeutic challenge in urological oncology. In order to make more drugs available to patients in the future, we identified amiodarone, a repurposed drug used in cardiology as a compound that inhibits bladder cancer in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0433","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:02:49Z","timestamp":1747044169000},"page":"906-920","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing Amiodarone for Bladder Cancer Treatment"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3429-8955","authenticated-orcid":false,"given":"Francisco J.","family":"Roa","sequence":"first","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-6581","authenticated-orcid":false,"given":"Maria","family":"Roubelakis","sequence":"additional","affiliation":[{"name":"2Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece."},{"name":"3Biomedical Research Foundation, Academy of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2552-6339","authenticated-orcid":false,"given":"Konstantinos","family":"Paschidis","sequence":"additional","affiliation":[{"name":"2Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece."},{"name":"3Biomedical Research Foundation, Academy of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2208-5305","authenticated-orcid":false,"given":"Nils C.H.","family":"van Creij","sequence":"additional","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-5635","authenticated-orcid":false,"given":"Florian","family":"Handle","sequence":"additional","affiliation":[{"name":"4XPseq Analytics GmbH, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-3559","authenticated-orcid":false,"given":"Manousos","family":"Makridakis","sequence":"additional","affiliation":[{"name":"3Biomedical Research Foundation, Academy of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5793-6235","authenticated-orcid":false,"given":"Shaman","family":"Narayanasamy","sequence":"additional","affiliation":[{"name":"5Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-895X","authenticated-orcid":false,"given":"Irina-Afrodita","family":"Balaur","sequence":"additional","affiliation":[{"name":"5Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-2111","authenticated-orcid":false,"given":"Aggeliki","family":"Tserga","sequence":"additional","affiliation":[{"name":"3Biomedical Research Foundation, Academy of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-5713","authenticated-orcid":false,"given":"Antonia","family":"Vlahou","sequence":"additional","affiliation":[{"name":"3Biomedical Research Foundation, Academy of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4591-6368","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric R.","family":"Santer","sequence":"additional","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-2323","authenticated-orcid":false,"given":"Per-Sonne","family":"Holm","sequence":"additional","affiliation":[{"name":"6Department of Oral and Maxilofacial Surgery, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-1671","authenticated-orcid":false,"given":"Michele","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"7Department of Urology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich Heine University of D\u00fcsseldorf, D\u00fcsseldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-9653","authenticated-orcid":false,"given":"Martin","family":"Puhr","sequence":"additional","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-1578","authenticated-orcid":false,"given":"Marika","family":"Mokou","sequence":"additional","affiliation":[{"name":"8Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-0316","authenticated-orcid":false,"given":"Maria","family":"Frantzi","sequence":"additional","affiliation":[{"name":"8Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8278-1618","authenticated-orcid":false,"given":"Reinhard","family":"Schneider","sequence":"additional","affiliation":[{"name":"5Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-2412","authenticated-orcid":false,"given":"Agnieszka","family":"Latosinska","sequence":"additional","affiliation":[{"name":"8Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-0306","authenticated-orcid":false,"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[{"name":"8Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-5880","authenticated-orcid":false,"given":"Venkata","family":"Satagopam","sequence":"additional","affiliation":[{"name":"5Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-6153","authenticated-orcid":false,"given":"Zoran","family":"Culig","sequence":"additional","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[{"name":"1Department of Urology, Medical University of Innsbruck, Innsbruck, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025060403233931900_bib1","volume-title":"Cancer Facts & Figures 2024","author":"American Cancer Society","year":"2024"},{"key":"2025060403233931900_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025060403233931900_bib3","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025060403233931900_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2025060403233931900_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"2025060403233931900_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"2025060403233931900_bib7","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025060403233931900_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol Res"},{"key":"2025060403233931900_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"2025060403233931900_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br J Cancer"},{"key":"2025060403233931900_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025060403233931900_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"2025060403233931900_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"2025060403233931900_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40261-023-01251-0","article-title":"Does therapeutic repurposing in cancer meet the expectations of having drugs at a lower price?","volume":"43","author":"Gonzalez-Fierro","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2025060403233931900_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-019-0609-0","article-title":"Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies","volume":"121","author":"Kita","year":"2019","journal-title":"Br J Cancer"},{"key":"2025060403233931900_bib16","doi-asserted-by":"crossref","first-page":"eaba4627","DOI":"10.1126\/scitranslmed.aba4627","article-title":"Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer","volume":"13","author":"Chrysostomou","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025060403233931900_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2022.03.009","article-title":"Molecular and pharmacological bladder cancer therapy screening: discovery of clofarabine as a highly active compound","volume":"82","author":"Ertl","year":"2022","journal-title":"Eur Urol"},{"key":"2025060403233931900_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/1535-7163.MCT-21-0613","article-title":"A preclinical study to repurpose spironolactone for enhancing chemotherapy response in bladder cancer","volume":"21","author":"Xu","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025060403233931900_bib19","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.7150\/ijbs.63125","article-title":"Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer","volume":"17","author":"Lin","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2025060403233931900_bib20","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1002\/1878-0261.12793","article-title":"Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer","volume":"14","author":"van der Horst","year":"2020","journal-title":"Mol Oncol"},{"key":"2025060403233931900_bib21","doi-asserted-by":"crossref","first-page":"106654","DOI":"10.1016\/j.phrs.2023.106654","article-title":"Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin \u03b15\/\u03b21-FAK\/Src axis: a novel strategy for drug application","volume":"188","author":"Wu","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025060403233931900_bib22","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.3390\/ijms241411852","article-title":"Sertindole, an antipsychotic drug, curbs the STAT3\/BCL-xL axis to elicit human bladder cancer cell apoptosis in vitro","volume":"24","author":"Hsu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025060403233931900_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/biomedicines12030647","article-title":"Exploring darunavir, rilpivirine and etravirine as potential therapies for bladder cancer: efficacy and synergistic effects","volume":"12","author":"Pereira","year":"2024","journal-title":"Biomedicines"},{"key":"2025060403233931900_bib24","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.3390\/cancers12123519","article-title":"A novel pipeline for drug repurposing for bladder cancer based on patients' omics signatures","volume":"12","author":"Mokou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025060403233931900_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-0716-3291-8_4","article-title":"A drug repurposing pipeline based on bladder cancer integrated proteotranscriptomics signatures","volume":"2684","author":"Mokou","year":"2023","journal-title":"Methods Mol Biol"},{"key":"2025060403233931900_bib26","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"2025060403233931900_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"2025060403233931900_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.32556","article-title":"Proteome-based classification of nonmuscle invasive bladder cancer","volume":"146","author":"Stroggilos","year":"2020","journal-title":"Int J Cancer"},{"key":"2025060403233931900_bib29","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/cancers14102542","article-title":"Gene expression monotonicity across bladder cancer stages informs on the molecular pathogenesis and identifies a prognostic eight-gene signature","volume":"14","author":"Stroggilos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025060403233931900_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150024","article-title":"BcCluster: a bladder cancer database at the molecular level","volume":"2","author":"Bhat","year":"2016","journal-title":"Bladder Cancer"},{"key":"2025060403233931900_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/BLC-180167","article-title":"Systematic review: characteristics and preclinical uses of bladder cancer cell lines","volume":"4","author":"Zuiverloon","year":"2018","journal-title":"Bladder Cancer"},{"key":"2025060403233931900_bib32","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","article-title":"Targeting Stat3 abrogates EGFR inhibitor resistance in cancer","volume":"18","author":"Sen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025060403233931900_bib33","doi-asserted-by":"crossref","first-page":"70750","DOI":"10.18632\/oncotarget.12218","article-title":"Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models","volume":"7","author":"Frantzi","year":"2016","journal-title":"Oncotarget"},{"key":"2025060403233931900_bib34","doi-asserted-by":"crossref","first-page":"e0189470","DOI":"10.1371\/journal.pone.0189470","article-title":"Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways","volume":"12","author":"Bognar","year":"2017","journal-title":"PLoS One"},{"key":"2025060403233931900_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"2025060403233931900_bib36","doi-asserted-by":"crossref","first-page":"9495920","DOI":"10.1155\/2022\/9495920","article-title":"Influence of antibiotic administration on the urinary bladder cancer early recurrence rate","volume":"2022","author":"Kowalski","year":"2022","journal-title":"J Oncol"},{"key":"2025060403233931900_bib37","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1007\/s13277-014-2959-9","article-title":"Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation","volume":"36","author":"Greife","year":"2015","journal-title":"Tumour Biol"},{"key":"2025060403233931900_bib38","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.18632\/oncotarget.27767","article-title":"MEK is a promising target in the basal subtype of bladder cancer","volume":"11","author":"Merrill","year":"2020","journal-title":"Oncotarget"},{"key":"2025060403233931900_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.amjms.2018.01.011","article-title":"The antiarrhythmic drug, amiodarone, decreases AKT activity and sensitizes human acute myeloid leukemia cells to apoptosis by ABT-263","volume":"355","author":"Ketchem","year":"2018","journal-title":"Am J Med Sci"},{"key":"2025060403233931900_bib40","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.18632\/oncotarget.24385","article-title":"Amiodarone promotes cancer cell death through elevated truncated SRSF3 and downregulation of miR-224","volume":"9","author":"Chang","year":"2018","journal-title":"Oncotarget"},{"key":"2025060403233931900_bib41","doi-asserted-by":"crossref","first-page":"18034","DOI":"10.1038\/s41598-020-75142-1","article-title":"Low dose amiodarone reduces tumor growth and angiogenesis","volume":"10","author":"Steinberg","year":"2020","journal-title":"Sci Rep"},{"key":"2025060403233931900_bib42","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/ijms23031544","article-title":"Involvement of mitochondrial mechanisms and cyclooxygenase-2 activation in the effect of desethylamiodarone on 4T1 triple-negative breast cancer line","volume":"23","author":"Gallyas","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025060403233931900_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/neuonc\/noq195","article-title":"Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation","volume":"13","author":"Kim","year":"2011","journal-title":"Neuro Oncol"},{"key":"2025060403233931900_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: should it Be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2019","journal-title":"Pharm Res"},{"key":"2025060403233931900_bib45","doi-asserted-by":"crossref","first-page":"42976","DOI":"10.18632\/oncotarget.5621","article-title":"Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"2025060403233931900_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"2025060403233931900_bib47","doi-asserted-by":"crossref","first-page":"e147025","DOI":"10.1172\/JCI147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"key":"2025060403233931900_bib48","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.21873\/anticanres.16994","article-title":"STAT3 contributes a favorable response to pembrolizumab through IFN-\u03b3-induced apoptosis in urothelial cancer","volume":"44","author":"Fuchizawa","year":"2024","journal-title":"Anticancer Res"},{"key":"2025060403233931900_bib49","doi-asserted-by":"crossref","first-page":"116676","DOI":"10.1016\/j.taap.2023.116676","article-title":"Amiodarone but not propafenone impairs bioenergetics and autophagy of human myocardial cells","volume":"477","author":"Kraj\u010dov\u00e1","year":"2023","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025060403233931900_bib50","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2025060403233931900_bib51","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.2013.505","article-title":"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation","volume":"109","author":"Seront","year":"2013","journal-title":"Br J Cancer"},{"key":"2025060403233931900_bib52","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025060403233931900_bib53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41467-020-20491-8","article-title":"Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML","volume":"12","author":"Oki","year":"2021","journal-title":"Nat Commun"},{"key":"2025060403233931900_bib54","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-024-45132-2","article-title":"The IL6\/JAK\/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer","volume":"15","author":"Amara","year":"2024","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0433\/3604329\/crc-24-0433.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/906\/3612069\/crc-24-0433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/906\/3612069\/crc-24-0433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:23:56Z","timestamp":1749007436000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/6\/906\/762821\/Repurposing-Amiodarone-for-Bladder-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0433","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29234480","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234492","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234483","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234495","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234474","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234486","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234498","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234477","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234510","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234504","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29234507","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7856603","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}